US judge certifies investor class action alleging Pfizer concealed risks of Celebrex, Bextra
This article was originally published in Scrip
Executive Summary
A New York federal judge has certified a class of Pfizer investors accusing the company and its top corporate officers of violating US securities law through alleged misrepresentations over a certain period on the safety and cardiovascular risks associated with the COX-2 inhibitors, Celebrex (celecoxib) and Bextra (valdecoxib).